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Introduction: Melioidosis, caused by the environmentally-acquired bacterium Burkholderia pseudomallei,
is increasingly recognised as a globally significant public health problem, although difficult to diagnose
and manage. We aimed to review all cases diagnosed in the UK since 2010, when notification became
a legal requirement. This was compared with statutory reporting to assess completeness of surveillance.
Methods: A novel dataset was compiled comprising routinely collected clinical and demographic details
for isolates of B. pseudomallei referred to Public Health England’s reference laboratory. Isolates were
cross-referenced with an existing database of mandatory reports of B. pseudomallei made under the
Health Protection (Notification) Regulations 2010 to determine completeness of surveillance. The litera-
ture was also searched for missed non-referred or reported cases.
Results: Forty-six UK cases of melioidosis were identified from January 2010-July 2019. The majority of
affected patients were male (65.2%); median age was 53. Four had cystic fibrosis. Other co-morbidities
were poorly captured by current surveillance mechanisms. Respiratory disease, sepsis and abscess forma-
tion were the most common presenting features. Eighteen had acquired infection in Thailand; two cases
were associated with travel to Nigeria. 40 UK cases were confirmed as B. pseudomallei by the reference
laboratory. Nineteen of the identified cases were not found on the database of notified causative agents.
Five patients had been notified with no confirmatory isolate received.
Discussion: Discordance between mandatory notification and isolate referral emphasises the challenges
in routine epidemiological surveillance, even in a well-resourced, high-income country. The wide variety
of presentations highlights the difficulties in clinical diagnosis. Cases identified following travel to Africa
add further evidence that the disease is more widespread than previously thought. Sixteen patients
required intensive care management, underlining challenges faced in resource limited settings.
Individualised pre-travel counselling should be performed in travellers with high-risk comorbidities such
as cystic fibrosis.
 2020 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Melioidosis is an environmentally-acquired infection caused by
the organism Burkholderia pseudomallei, the clinical manifestations
of which can vary extensively though most commonly include
fever, pneumonia and abscess formation.1–3 It is noteworthy for
its high case fatality rate (10–50%). Whilst it is well known to be
of public health importance in south-east Asia and northernAustralia, it is increasingly being recognised in other tropical
regions.4 However it is grossly under-diagnosed and under-
reported in many places due to its numerous clinical manifesta-
tions and the paucity of diagnostic facilities able to identify the
causative organism.5 Recent studies have suggested that melioido-
sis may have been responsible for as many as 4.6 million disability-
adjusted life years (DALYs) and 89,000 deaths globally in 2015.6
Furthermore, it is considered to have biothreat potential, resulting
in the classification of B. pseudomallei as a Tier 1 Select Agent in the
USA and schedule 5 pathogen in the UK. For these reasons
melioidosis is considered to be a disease of high public health
significance.
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may also be imported into temperate countries, with fifteen cases
known to have been confirmed in the UK between 1988–1998 and
twenty-three between 1997 and 2007.7,8 Many of these were not
formally reported through the (then voluntary) laboratory-based
surveillance system. The introduction of the Health Protection
(Notification) Regulations 2010 represented the first time that lab-
oratories were legally required to report the identification of cer-
tain agents, including B. pseudomallei, to Public Health England
(PHE).9 We undertook this review primarily in order to determine
the completeness and accuracy of routine UK surveillance systems
for melioidosis since notification by laboratories became a statu-
tory requirement on 1st October 2010.Methods
Three sources of data were used to identify cases of melioidosis
in the UK occurring between 1st January 1010 and 31st July 2019
to undertake this review:
1. Notifications of B. pseudomallei made by laboratories under the
Health Protection (Notification) Regulations 2010 extracted
from the Notifications of Infectious Diseases (NOIDs) database.
2. Isolates referred to PHE’s Antimicrobial Resistance and Health-
care Associated Infections (AMRHAI) Reference Unit for confir-
mation of B. pseudomallei identity were extracted from the
‘MOLIS’ laboratory information system (CompuGroup Medical,
Wetteren, Belgium). Only those confirmed as B. pseudomallei
were included in comparison with the NOIDs dataset. Referral
of isolates is voluntary but, whilst a variety of techniques can
be used to identify B. pseudomallei in diagnostic laboratories,
species-specific PCR10 confirmation for suspected B. pseudoma-
llei isolates is only available in the UK at this reference
laboratory.
3. A literature search was performed with a year restriction of
2010, finding 399 papers that were screened by title and, where
relevant, abstract. Search terms of the Ovid database included
Melioid* or Burkholderia pseudomallei or Pseudomonas pseudo-
mallei or Whitmore* AND United Kingdom or UK or England
or Wales or Scotland or Northern Ireland or Ireland or British
or English or Welsh or Scottish or Irish or travel* or return* or
import* or touris* or visit*.
Records were de-duplicated and manually reviewed including
request forms and accompanying letters. Datasets were compared
to identify patients who had isolates received at AMRHAI for con-
firmation that were not notified to NOIDs by the referring labora-
tory, as well as notifications to NOIDs for which isolates were not
sent for confirmation.
We excluded cases of melioidosis diagnosed on the basis of
serological tests for a variety of reasons, including interpretation
of equivocal ELISA results and problems with the sensitivity and
specificity of melioidosis serodiagnosis more generally.11 Its use
by PHE was discontinued in 2014.Results
Completeness of notification
Initial searching of the MOLIS system yielded 97 samples tested
by B. pseudomallei PCR. Of these, 10 were excluded as B. pseudoma-
llei PCR was negative. A further six were excluded as they repre-
sented internal audit and quality control samples. This led to a
final dataset of 81 isolates confirmed as B. pseudomallei over the2
period of this review. These isolates were received from a total of
46 individual patients.
Six patients were managed outside the UK, but with samples
sent to AMRHAI for confirmatory testing – two from The Nether-
lands, two from the Republic of Ireland, one from Italy and one
from Seychelles. Thus, confirmed B. pseudomallei isolates were
received from 40 UK cases during the study period.
The literature search identified one additional published case of
melioidosis imported into the UK for which an isolate had not been
received at PHE and there was no NOIDs database notification. We
thus initially identified 41 cases of imported melioidosis into the
UK from these sources during the study period.
The NOIDs database yielded 132 distinct melioidosis notifica-
tion events from local laboratories. These notifications related to
27 patients.
Twenty-two of these were included in both the NOIDs and
MOLIS datasets, whilst five were not on the MOLIS system as no
isolates had been received at AMRHAI for confirmation. Microbio-
logical confirmation of the diagnosis in these patients was based
on serology in one, culture from a corneal specimen in one, and
culture from blood or sputum in three; methods used to confirm
the identity of the organism in the reporting laboratories were
not available.
Overall, 19 of the 46 patients (41.3%) with imported melioidosis
were not notified to NOIDs despite this being mandated by the
Health Protection (Notification) Regulations 2010. Fig. 1 sum-
marises case identification from each dataset.Clinical and epidemiological features
Of the 46 patients, 30 were male (65.2%). The median age was
53 years with a range of 17–71 years. Three patients were visiting
the UK when they became unwell, one each from Borneo (country
unspecified), India and Nigeria. As only basic demographic details
were available for the five cases that were reported through NOIDs
alone, these were excluded from subsequent analyses (clinical fea-
tures, risk factors etc.), meaning that the data below are based on
41 patients (see Table 1).
Based on reported clinical details accompanying isolate referral
requests, the most common presenting symptom was of fever,
recorded in 34 patients (82.9%). Twenty-two patients were bacter-
aemic at presentation (53.7%). Other common findings were respi-
ratory disease, skin and soft tissue abscess, and genito-urinary
infection including prostatic abscess, which were seen in 36.6%,
31.7% and 14.6% of patients respectively.
Thirty-nine percent of patients were managed at some point on
an intensive care or high dependency unit. Twelve percent of
patients were managed as outpatients, either representing those
with cystic fibrosis or bronchiectasis with chronic infection/coloni-
sation, or uncomplicated skin and soft tissue infections.
Although treatment and outcome data are not recorded as part
of routine surveillance, information available at PHE showed at
least three of the patients for whom isolates were received had
died.
Thailand was the most common country of acquisition of dis-
ease (43.9% of cases), followed by India and Nigeria, implicated
in three and two cases respectively. Six patients had visited multi-
ple countries, making it difficult to identify a single source of expo-
sure. Countries visited by these six included Cambodia, China,
India, Nepal, Sri Lanka, Thailand and Vietnam, all of which are
known to be melioidosis-endemic apart from Nepal, where melioi-
dosis is believed to exist but is as yet unconfirmed.4 Travel history
was unspecified for 17.1% of patients.
Of the 46 identified cases of melioidosis, nine of these had been
published in the literature (19.6%) including one of the two cases
Fig. 1. Flow diagram of cases from each of the datasets contributing to the final total of 46 UK cases of melioidosis between 2010 and 2019.
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material.Discussion
Melioidosis was first described in July 1912 by Alfred Whitmore
and CS Krishnaswami amongst morphine injectors, prisoners and
the malnourished, presenting with disseminated abscesses and
sepsis in Rangoon.12 Over the past 30 years it has become apparent
that the disease is significantly under-diagnosed and is probably a
more important cause of deaths worldwide than many tropical dis-
eases which, unlike melioidosis, are officially regarded as ‘ne-
glected’.6 With the rising prevalence of conditions that increase
the risk of melioidosis, climate change and popularity of travel to
melioidosis-endemic areas, it is likely that global melioidosis inci-
dence will also increase.13,14 In theory, surveillance should be close
to complete in countries like the UK, where the disease is not ende-
mic, diagnostic laboratories are widespread and well-equipped,
and reporting of melioidosis by laboratories is now mandatory.
This study confirmed a rising incidence of melioidosis imported
into the UK in comparison with previous series7,8 but has shown
many cases are still not being formally notified and acts as a remin-
der that routinely collected ‘official’ data, even for rare diseases of
public health concern such as melioidosis, may be unreliable.
The NOIDs database represents the official record of UK melioi-
dosis cases since B. pseudomallei became a statutorily notifiable
pathogen. This study found 41.3% of patients with melioidosis
were not notified by diagnostic laboratories. The fact that a case
was reported in the literature without either an isolate or a notifi-3
cation being sent to PHE suggests there may have been additional
cases not captured in our three datasets. This represents a defi-
ciency in routine reporting in the UK and suggests there is room
for improvement in these systems. Possible mechanisms to
improve this situation might rely on additional prompts, such as
the inclusion of a reminder to the referring laboratory to notify
causative agents on reference laboratory reports, or penalties for
those which fail to report. Although there are potential financial
penalties for laboratories that fail to notify pathogens, as far as
we are aware these have never been imposed since the Health Pro-
tection (Notification) Regulations 2010 came into effect.
The degree of under-reporting seen in a well-resourced, high-
income country with statutory notification legislation adds weight
to the suggestion that under-reporting of melioidosis is a signifi-
cant problem globally. Since allocation of resources and policies
in lower- and middle-income settings are often driven by national
surveillance data, underreporting of cases and fatalities may lead
to a vicious cycle of inadequate surveillance, under-recognition
and failure to develop and implement appropriate disease control
programmes. Recent work in Thailand suggests completeness of
national surveillance data for melioidosis could be successfully
enhanced simply by integrating data from readily available
datasets.15
Not all notifying laboratories sent an isolate to PHE for confir-
mation. Whilst not mandatory, the potential for misidentification
by local MALDI-TOF or other identification methods must be
remembered.16,17 There is also potential risk to laboratory staff
working with B. pseudomallei.18 From a public health perspective,
if more isolates are received at the reference laboratory there can
be more accurate epidemiological monitoring of imported melioi-
Table 1
Patient demographics and clinical details.
Variable Number of
patients (%)
Demographics Male sex 30 (65.2)
Median age [range] 53 [17–71]
Age < 25 6 (13.0)
Age 25–40 10 (21.7)
Age 41–55 14 (30.4)
Age > 55 16 (34.7)
Co-morbidities Cystic fibrosis 4 (9.8)
End-stage renal failure 2 (4.9)
Type 2 diabetes 2 (4.9)
Bronchiectasis 1 (2.4)
Clinical features Fever 34 (82.9)
Bacteraemia 22 (53.7)









Skin lesion or ulcer 2 (4.9)
Neurological 2 (4.9)
Care setting Intensive care/high
dependency
16 (39.0)
General ward 15 (36.6)
Outpatient 5 (12.2)
Unspecified 10 (24.4)










Multiple countries visited 6 (14.6)
Not specified 7 (17.1)
Baseline demographic characteristics, documented co-morbidities, clinical presen-
tation and travel history of 46 patients. Note for clinical features patients may have
contributed to more than one category depending on their presentation. Respira-
tory disease includes pneumonia, cough, breathlessness and cystic fibrosis. Five
cases solely reported to NOIDs only contributed to demographics.
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Typing (MLST) / Variable Number Tandem Repeat (VNTR) analysis,
and confirmation of antimicrobial susceptibility. Furthermore, the
true number of cases in the UK may well be higher if some patients
are presumptively treated in the absence of culture confirmation,
especially given the limitations of sensitivity of culture particularly
where selective media are not used, though the need for long peri-
ods of treatment to avoid relapses means that standard antibiotic
regimes may well not eradicate the infection.19,20
Although we have attempted to summarise the clinical and epi-
demiological features of the patients in this study, the data high-
light the shortcomings of using routinely collected surveillance
data for this purpose. For example only 4.9% of the cases in this ser-
ies were known to be diabetic, whereas in other series this is the
commonest predisposing risk factor for melioidosis, present in
more than 50% of patients.21,22 Conversely, the proportion of
patients with cystic fibrosis and bronchiectasis in this series
(12.1%) is higher than that from melioidosis-endemic areas. The
Cystic Fibrosis Trust in the UK has produced specific guidance
about melioidosis for patients with the condition planning to travel
to melioidosis-endemic areas.23 Thailand was the most common
country implicated in acquisition, reflecting both high endemicity
and frequency of travel.4,13 The occurrence of two cases associated
with Nigeria is worthy of note.4
Conclusion
The under-recognition and under-reporting of melioidosis glob-
ally remains a challenge. As both non-communicable diseases and
international travel become more prevalent, clinicians everywhere
need to be mindful of the potential for imported infections such as
melioidosis and the provision of individualised pre-travel coun-
selling for high risk patients such as those with cystic fibrosis.
The extent of under-reporting of melioidosis in a well-resourced
setting such as the UK not only highlights the difficulties faced
by developing endemic countries in assessing their own disease
burden and allocating appropriate priority to melioidosis, but also
acts as a warning to treat all surveillance data with a degree of cau-
tion. In high-income settings these challenges should be amenable
to an IT solution, but in many melioidosis-endemic areas, better
and locally appropriate diagnostic techniques are an even more
urgent priority.
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